Safety and Immunogenicity of a New Formulation of Euvichol®

Key facts

Sponsor

International Vaccine Institute

Principal Investigator

Laura Digilio, MD

International Vaccince Institute

Intervention

Test Oral Cholera Vaccine(biological)

Enrollment

442 enrolled

Eligibility

1-40 years · All sexes

Timeline

2016 – 2016

Collaborators

EuBiologics Co.,Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cholera

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07509047
  Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children
  International Vaccine Institute
• RECRUITINGPHASE4NCT07487077
  Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya
  Albert B. Sabin Vaccine Institute
• RECRUITINGPHASE3NCT07304284
  Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus
  International Vaccine Institute
• RECRUITINGNANCT06455852
  Vaccine- and Infection-derived Correlates of Protection for Cholera.
  Massachusetts General Hospital
• RECRUITINGNANCT06498817
  Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7)
  Johns Hopkins Bloomberg School of Public Health
• RECRUITINGNANCT06003816
  Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)
  Johns Hopkins Bloomberg School of Public Health
• RECRUITINGNANCT05166850
  Preventative Intervention for Cholera for 7 Days
  Johns Hopkins Bloomberg School of Public Health
• ACTIVE NOT RECRUITINGPHASE2NCT04326478
  Single Dose Azithromycin to Prevent Cholera in Children
  Massachusetts General Hospital

See all trials for Cholera →